EBM Fundamental Analysis - EASTWOOD BIO-MEDICAL CANADA

Fundamental Rating

Taking everything into account, EBM scores 0 out of 10 in our fundamental rating. EBM was compared to 15 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of EBM have multiple concerns. EBM is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

EBM had negative earnings in the past year.

EBM had a negative operating cash flow in the past year.

In the past 5 years EBM always reported negative net income.

In the past 5 years EBM always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -199.32%, EBM is doing worse than 86.67% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-199.32%
ROE	N/A
ROIC	N/A

ROA(3y)-101.2%

ROA(5y)-96.45%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EBM has a better Gross Margin (64.53%) than 86.67% of its industry peers.

EBM's Gross Margin has improved in the last couple of years.

EBM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	64.53%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y11.47%

GM growth 5Y8.17%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EBM does not have a ROIC to compare to the WACC, probably because it is not profitable.

EBM has about the same amout of shares outstanding than it did 1 year ago.

EBM has about the same amout of shares outstanding than it did 5 years ago.

Compared to 1 year ago, EBM has a worse debt to assets ratio.

2.2 Solvency

EBM has an Altman-Z score of -38.69. This is a bad value and indicates that EBM is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of EBM (-38.69) is worse than 86.67% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-38.69

ROIC/WACCN/A

WACC7.94%

2.3 Liquidity

A Current Ratio of 0.03 indicates that EBM may have some problems paying its short term obligations.

EBM has a Current ratio of 0.03. This is amonst the worse of the industry: EBM underperforms 86.67% of its industry peers.

EBM has a Quick Ratio of 0.03. This is a bad value and indicates that EBM is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Quick ratio value of 0.03, EBM is not doing good in the industry: 86.67% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.03
Quick Ratio	0.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.82% over the past year.

EBM shows a small growth in Revenue. In the last year, the Revenue has grown by 0.78%.

The Revenue for EBM have been decreasing by -11.50% on average. This is quite bad

EPS 1Y (TTM)2.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-21.05%

Revenue 1Y (TTM)0.78%

Revenue growth 3Y-10.55%

Revenue growth 5Y-11.5%

Sales Q2Q%-43.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EBM. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EBM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EASTWOOD BIO-MEDICAL CANADA

TSX-V:EBM (8/6/2025, 7:00:00 PM)

0.41

-0.02 (-4.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)06-30 2025-06-30

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners0.17%

Ins Owner ChangeN/A

Market Cap28.24M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	42.96
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.01

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0

FCFYN/A

OCF(TTM)0

OCFYN/A

SpS0.01

BVpS-0.02

TBVpS-0.02

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-199.32%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	64.53%
FCFM	N/A

ROA(3y)-101.2%

ROA(5y)-96.45%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y11.47%

GM growth 5Y8.17%

F-Score4

Asset Turnover2.79

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.03
Quick Ratio	0.03
Altman-Z	-38.69

F-Score4

WACC7.94%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)2.82%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-21.05%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)0.78%

Revenue growth 3Y-10.55%

Revenue growth 5Y-11.5%

Sales Q2Q%-43.2%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y12.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y77.48%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y75.51%

OCF growth 3YN/A

OCF growth 5YN/A

EASTWOOD BIO-MEDICAL CANADA (EBM.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens